Author
NHD Technical Team
NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.
-
Evidence & Quality Guides
CJC-1295 Without DAC: Sequence, Naming and a Quality Checklist
-
Published Study Reviews
AOD-9604 OPTIONS Study: Primary Outcome, Null Result and Evidence Limits
-
Evidence & Quality Guides
AOD-9604 Evidence Boundary: GH Fragment Biology, Failed Development and Lot Identity
-
Published Study Reviews
CJC-1295 With DAC in Healthy Adults: GH, IGF-1 and Half-Life Data
-
Evidence & Quality Guides
CJC-1295 With DAC: Albumin Binding, Identity Controls and FDA Safety Context
-
Published Study Reviews
CJC-1295 Without DAC: Why the Classic Long-Acting Trial Does Not Apply
-
Evidence & Quality Guides
SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters
-
Published Study Reviews
Ibutamoren (MK-677) in Older Adults: Two-Year Body-Composition Data and the Missing Functional Gain
-
Evidence & Quality Guides
MK-677 / Ibutamoren: Clinical Status, Heart-Failure Signal and Material Questions
-
Published Study Reviews
Ipamorelin After Bowel Surgery: The Randomized Trial and Its Null Primary Endpoint
-
Evidence & Quality Guides
Ipamorelin Evidence and Safety: Route-Specific Data and Peptide Characterization
-
Published Study Reviews
GHK-Cu After Laser Resurfacing: What the Randomized Study’s 13 Completers Showed